↓ Skip to main content

Communicating mild cognitive impairment diagnoses with and without amyloid imaging

Overview of attention for article published in Alzheimer's Research & Therapy, May 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Communicating mild cognitive impairment diagnoses with and without amyloid imaging
Published in
Alzheimer's Research & Therapy, May 2017
DOI 10.1186/s13195-017-0261-y
Pubmed ID
Authors

Joshua D. Grill, Liana G. Apostolova, Szofia Bullain, Jeffrey M. Burns, Chelsea G. Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler, Oscar L. Lopez, Mark Mapstone, Aimee Pierce, Gil Rabinovici, J. Scott Roberts, Seyed Ahmad Sajjadi, Edmond Teng, Jason Karlawish

Abstract

Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. We convened a workgroup to formulate recommendations for clinicians providing care to MCI patients. Clinicians should use the MCI diagnosis to validate patient and family concerns and educate them that the patient's cognitive impairment is not normal for his or her age and education level. The MCI diagnosis should not be used to avoid delivering a diagnosis of dementia. For patients who meet Appropriate Use Criteria after standard-of-care clinical workup, amyloid imaging may position specialists to offer more information about etiology and prognosis. Clinicians must set appropriate expectations, including ensuring that patients and families understand the limitations of amyloid imaging. Communication of negative results should include that patients remain at elevated risk for dementia and that negative scans do not indicate a specific diagnosis or signify brain health. Positive amyloid imaging results should elicit further monitoring and conversations about appropriate advance planning. Clinicians should offer written summaries, including referral to appropriate social services. In patients with MCI, there is a need to devote considerable time and attention to patient education and shared decision-making. Amyloid imaging may be a tool to aid clinicians. Careful management of patient expectations and communication of scan results will be critical to the appropriate use of amyloid imaging information.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 16%
Researcher 12 15%
Other 9 11%
Student > Doctoral Student 8 10%
Student > Master 8 10%
Other 19 23%
Unknown 12 15%
Readers by discipline Count As %
Medicine and Dentistry 19 23%
Psychology 11 14%
Nursing and Health Professions 7 9%
Neuroscience 7 9%
Social Sciences 6 7%
Other 15 19%
Unknown 16 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2019.
All research outputs
#1,377,375
of 19,338,160 outputs
Outputs from Alzheimer's Research & Therapy
#229
of 1,005 outputs
Outputs of similar age
#31,209
of 277,560 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 19,338,160 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,005 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.1. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them